Home » Stocks » GNFT

Genfit S.A. (GNFT)

Stock Price: $5.40 USD -0.32 (-5.59%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 206.72M
Revenue (ttm) 46.02M
Net Income (ttm) -73.20M
Shares Out 36.18M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $5.40
Previous Close $5.72
Change ($) -0.32
Change (%) -5.59%
Day's Open 5.40
Day's Range 5.27 - 5.51
Day's Volume 17,174
52-Week Range 3.63 - 22.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #GNFT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA

GlobeNewsWire - 1 week ago

Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and live...

GlobeNewsWire - 1 week ago

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and live...

GlobeNewsWire - 2 weeks ago

Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver...

GlobeNewsWire - 2 weeks ago

Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver...

Business Wire - 1 month ago

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) ...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

Business Wire - 1 month ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

GlobeNewsWire - 1 month ago

Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of pati...

GlobeNewsWire - 1 month ago

Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of pati...

GlobeNewsWire - 2 months ago

Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of pati...

GlobeNewsWire - 2 months ago

Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patie...

GlobeNewsWire - 2 months ago

                   

Seeking Alpha - 3 months ago

GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

       

24/7 Wall Street - 3 months ago

Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).

Other stocks mentioned: LH
GlobeNewsWire - 3 months ago

       

Other stocks mentioned: LH
GlobeNewsWire - 3 months ago

Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and ...

GlobeNewsWire - 4 months ago

Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and ...

GlobeNewsWire - 4 months ago

Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liv...

GlobeNewsWire - 5 months ago

Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patie...

GlobeNewsWire - 6 months ago

       

Seeking Alpha - 7 months ago

Genfit: Beaten Down But Not Dead

Zacks Investment Research - 7 months ago

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GuruFocus - 8 months ago

Genfit’s (NASDAQ:GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceutical...

Benzinga - 8 months ago

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Other stocks mentioned: CBAY
The Motley Fool - 8 months ago

One of the company's pipeline candidates flopped in a late-stage clinical trial.

Investors Business Daily - 8 months ago

Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.

Zacks Investment Research - 9 months ago

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GuruFocus - 9 months ago

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...

Other stocks mentioned: BMY, ICPT, MDGL, NVS, PTCT, RHHBY
Seeking Alpha - 9 months ago

Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Genfit.

GuruFocus - 1 year ago

A French biopharmaceutical company hopes to become the first to gain approval of a drug to treat a widespread liver disease.

The Motley Fool - 1 year ago

Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?

Other stocks mentioned: ICPT
Benzinga - 1 year ago

Genfit (NASDAQ: GNFT) on Monday afternoon announced a partnership with Terns Pharmaceuticals to develop and commercialize Elafibranor in Greater China.

Seeking Alpha - 1 year ago

Genfit expects to report interim results from its phase 3 NASH study, which is expected to be read out by the end of 2019.

Seeking Alpha - 1 year ago

Genfit received Breakthrough Therapy Designation from the FDA for its Elafibranor to treat patients with primary biliary cholangitis.

The Motley Fool - 1 year ago

They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

Other stocks mentioned: CARA, EDIT

About GNFT

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-indu... [Read more...]

Industry
Biotechnology
IPO Date
Mar 27, 2019
CEO
Pascal Prigent
Employees
203
Stock Exchange
NASDAQ
Ticker Symbol
GNFT
Full Company Profile

Financial Performance

In 2019, Genfit's revenue was 40.96 million, an increase of 446.58% compared to the previous year's 7.49 million. Losses were -65.14 million, -18.08% less than in 2018.

Financial numbers in millions EUR.
Financial Statements